PATENT CLAIM ANALYSIS

Application Number: 16179174
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "256000"]

Abstract:
The present invention is directed to novel protein kinase inhibitors comprising the chemical compound N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-(3-hydroxypyrrolidin-1-yl)pyrimidin-4-yl]amino]thiazole-5-carboxamide, its pharmaceutically acceptable salts, enantiomers, and enantiomeric mixtures, and methods of use to treat protein kinase-mediated diseases or conditions.

Claim (Index 9):
The method of  claim 8 , wherein the autoimmune disease is at least one of systemic lupus erythematosus (SLE), transplant rejection, multiple sclerosis (MS), systemic sclerosis (SSc), primary Sj\u00f6gren's syndrome (pSS), rheumatoid arthritis (RA), and psoriasis.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.22727
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15839469', '15839332', '13403394', '13971793', '14521766']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7532186428935685
- 35 USC 102 Novelty (BERT): 0.5613923853355984
- Combined Prediction Score: 0.7340360171377716
- Mean Citation Score: 357.999914
- Max Citation Score: 434.35107
- Similarity Product: 325.36292383779823

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test